Fundraising Fox
Keros Therapeutics
NASDAQ: KROSUnicorn · $1.1BLexington, US · Founded 2016 · 125 employees on LinkedIn · 4 known investors
Find your way into Keros Therapeutics
Sign up to find every way you can get introduced to Keros Therapeutics
- Your email: who you already know at Keros Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Keros Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart. Its pipeline targets neuromuscular diseases and ineffective hematopoiesis in myelodysplastic syndromes and myelofibrosis.
Founders & leadership
Keros Therapeutics was founded in 2016 by Jasbir S. Seehra and Jasbir Seehra.
Board
Investors · 4
How we know: Arkin Capital's portfolio page · Not right? Tell us
How we know: Foresite Capital's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: OrbiMed's portfolio page · the S-1 prospectus · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: Pontifax Venture Capital's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$78.5M disclosed across 3 of 5 rounds · 1900–2020
▶$56MraisedMar 2020 · 20 investors · OtherRule 506(b)
- Keith RegnanteExecutive Officer
- Jenn LacheyExecutive Officer
- Claudia OrdonezExecutive Officer
- Jasbir SeehraExecutive Officer, Director
- Nima FarzanDirector
- Alon LazarusDirector
- Ran NussbaumDirector
- Zafrira AvnurDirector
- Carl GordonDirector
- Julius KnowlesDirector
- Offering amount
- $56M
- Amount sold
- $56M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$11.5MraisedNov 2018 · 9 investors · BiotechnologyRule 506(b)
- Alon LazarusDirector
- Ran NussbaumDirector
- Julius KnowlesDirector
- Zafrira AvnurDirector
- Jasbir S. SeehraExecutive Officer, Director
- Ohad HammerDirector
- Offering amount
- $23M
- Amount sold
- $11.5M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$11MraisedNov 2017 · 7 investors · BiotechnologyRule 506(b)
- Jasbir S. SeehraExecutive Officer, Director
- Julius KnowlesDirector
- Alon LazarusDirector
- Ohad HammerDirector
- Ran NussbaumDirector
- Offering amount
- $11M
- Amount sold
- $11M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Keros Therapeutics do?
- Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart. Its pipeline targets neuromuscular diseases and ineffective hematopoiesis in myelodysplastic syndromes and myelofibrosis.
- Who founded Keros Therapeutics?
- Keros Therapeutics was founded by Jasbir S. Seehra, Jasbir Seehra in 2016.
- Who are Keros Therapeutics's investors?
- Keros Therapeutics's investors include Arkin Capital, Foresite Capital, OrbiMed, Pontifax Venture Capital.
- How much funding has Keros Therapeutics raised?
- Keros Therapeutics has disclosed $78.5M raised across 3 of its 5 known rounds.
- Where is Keros Therapeutics headquartered?
- Keros Therapeutics is headquartered in Lexington, US.